Vertex Pharmaceuticals
Boston
Massachusetts
United States
862 articles about Vertex Pharmaceuticals
-
Vertex Pharmaceuticals (MA) Announces Plans to Enroll Additional Treatment Arm in Ongoing Phase 2 Combination Study of Telaprevir and VX-222 for the Treatment of People with Hepatitis C
11/10/2010
-
Vertex Pharmaceuticals (MA) Announces Webcast of its Presentation at the Credit Suisse Annual Healthcare Conference
11/8/2010
-
Vertex Pharmaceuticals (MA) Release: New Data From Phase 3 Studies Showed Superior SVR (Viral Cure) Rates Achieved with Telaprevir-Based Combination Therapy in People with Hepatitis C, Regardless of Race or Stage of Liver Disease
11/1/2010
-
Vertex Pharmaceuticals (MA) Reports Third Quarter 2010 Financial Results and Highlights Progress in Hepatitis C and Cystic Fibrosis Development Programs
10/26/2010
-
Vertex Pharmaceuticals (MA) Loss Widens, Drug Application Nears
10/26/2010
-
Vertex Pharmaceuticals (MA) Announces Start of a Phase 3b Study of Twice-Daily Telaprevir in People Not Treated Previously for Hepatitis C
10/26/2010
-
Vertex Pharmaceuticals (MA) Initiates Clinical Trial to Evaluate Combination Regimens of VX-770 and VX-809 Targeting the Defective Protein Responsible for Cystic Fibrosis
10/18/2010
-
Vertex Pharmaceuticals (MA) Announces the Date of its Third Quarter 2010 Financial Results Conference Call and Webcast
10/12/2010
-
Vertex Pharmaceuticals (MA) Announces Webcast of its Presentation at Citi's 5th Annual Biotech Day
10/1/2010
-
Vertex Pharmaceuticals (MA) Announces Exercise of Underwriter's Option to Purchase Additional Convertible Senior Subordinated Notes
9/24/2010
-
Vertex Pharmaceuticals (MA) Announces Proposed Public Offering of Convertible Senior Subordinated Notes
9/23/2010
-
Vertex Pharmaceuticals (MA) Announces Webcasts of its Presentations at Two Investor Conferences
9/17/2010
-
Vertex Pharmaceuticals (MA) Announces Webcasts of its Presentations at Two Investor Conferences
9/10/2010
-
Vertex Pharmaceuticals (MA), Johnson & Johnson Hepatitis C Drug Works After Others Fail Like Merck & Co., Inc.'s Boceprevir
9/9/2010
-
Vertex Pharmaceuticals (MA) Announces Webcast of its Presentation at the Canaccord Genuity 30th Annual Growth Conference
8/11/2010
-
Vertex Pharmaceuticals (MA) Reports Second Quarter 2010 Financial Results and Highlights Recent Business and Clinical Progress
7/29/2010
-
Vertex Pharmaceuticals (MA) Appoints Wayne J. Riley, M.D., To Its Board of Directors
7/14/2010
-
Vertex Pharmaceuticals (MA) Announces the Date of its Second Quarter 2010 Financial Results Conference Call and Webcast
7/12/2010
-
Vertex Pharmaceuticals (MA) Announces Webcasts of its Presentations at Three Investor Conferences
6/14/2010
-
Vertex Pharmaceuticals (MA) Announces Webcasts of its Presentations at Two Investor Conferences
6/1/2010